In Brief:
- Strict Penalty Introduced: Applicants submitting fabricated data face temporary debarment from filing fresh applications alongside existing penalties.
- Deterrent Effect: The measure aims to curb repeated violations across manufacturing, sales, and clinical trial submissions.
- Due Process Guaranteed: Penalties will only follow a mandatory show-cause notice, with a clear provision for appeal.
- Safeguarding Public Health: Stricter regulatory enforcement seeks to maintain data integrity and ensure public safety.
The Union Ministry of Health and Family Welfare has notified amendments to the Drugs Rules, 1945, introducing stringent provisions against applicants who submit fake, misleading, or fabricated data for regulatory approvals.
Under the newly notified provisions, licensing authorities—at both the Central and State levels—are empowered to debar non-compliant entities from submitting fresh applications for a specified duration. This debarment extends across key regulatory processes, including clinical trials, drug manufacturing, sales, and testing.
Previously, enforcement under the Drugs and Cosmetics Act, 1940, was limited to rejecting the specific application or cancelling existing licences. The addition of temporary debarment acts as a stronger deterrent against habitual violations.
